Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of Blood, Blood Forming Organs and Immunologic DisordersDRG 814-reticuloendothelial-and-immunity-disorders-with-mcc
    Ask Trek AI about this page

    Reticuloendothelial and Immunity Disorders with MCC: Inpatient Reimbursement Overview

    DRG 814 covers serious reticuloendothelial and immune system disorders coded with a Major Complication or Comorbidity, representing higher-acuity admissions that drive greater resource use. Understanding this Diagnosis-Related Group is important for inpatient reimbursement because Major Complication or Comorbidity status affects relative weights and payment determination under Medicare.

    Customize your policy alerts

    Sign up for drg 814 policy alerts

    Get alerted when payer policies referencing 814 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 814 Overview

    DRG 814 (Reticuloendothelial and Immunity Disorders with Major Complication or Comorbidity) encompasses inpatient admissions for serious disorders of the reticuloendothelial system and immune function that include at least one Major Complication or Comorbidity. Typical cases involve severe immune dysregulation, hematologic immune disorders, severe infections with immune compromise, or complications of immunotherapy requiring substantial resource use. This Diagnosis-Related Group matters for Medicare payment because the presence of a Major Complication or Comorbidity elevates relative weights and payment levels to reflect higher intensity of care and longer hospital stays. Accurate clinical documentation and coding determine assignment to this Diagnosis-Related Group and thus influence inpatient reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Acute immunomodulatory intervention trials: randomized controlled studies testing short-term immunomodulatory therapies or dosing strategies in hospitalized patients with severe reticuloendothelial and immune disorders who present with life-threatening complications (for example, severe hemophagocytic syndromes, fulminant autoimmune cytopenias, or acute cytokine storm presentations). These trials focus on early in-hospital outcomes such as time to clinical stabilization, need for intensive care support, and in-hospital mortality, and are relevant because rapid control of immune dysregulation can markedly change length of stay and resource intensity for patients in this DRG. Providers and payers benefit from evidence that identifies which acute interventions reduce ICU utilization and short-term complications.
    • Comparative effectiveness studies of second-line and maintenance strategies: prospective comparative studies (including pragmatic trials and observational comparative-effectiveness research) that evaluate different longer-term management approaches for patients who survived an acute hospitalization for reticuloendothelial or immune disorders but remain at high risk for relapse or complications. These studies enroll heterogeneous inpatients transitioning to subacute care or discharge to examine outcomes such as readmission rates, recurrent severe flares, transfusion dependence, and cumulative healthcare costs across treatment algorithms or care pathways. Results inform clinicians and payers about which maintenance strategies reduce readmissions and downstream costs while optimizing patient safety.
    • Post-discharge outcomes and health services research: longitudinal cohort studies and registry-based research tracking functional recovery, quality of life, infection rates, and healthcare utilization in the months to years after hospital discharge for patients coded under this DRG, including those with comorbid immune deficiencies or chronic reticuloendothelial dysfunction. These studies address real-world questions about predictors of prolonged rehabilitation needs, outpatient resource use (specialty visits, home infusion or transfusion services), and the economic impact of chronic complications. Findings are important for discharge planning, care coordination, and payer decisions about coverage for outpatient supports that may reduce costly readmissions.

    Related Codes

    799-SPLENIC-PROCEDURES-WITH-MCC

    Splenic Procedures with MCC: Inpatient Reimbursement Overview

    800-SPLENIC-PROCEDURES-WITH-CC

    Splenic Procedures with CC: Inpatient Reimbursement Overview

    801-SPLENIC-PROCEDURES-WITHOUT-CC-MCC

    Splenic Procedures without CC/MCC: Inpatient Reimbursement Overview

    802-OTHER-O-R-PROCEDURES-OF-THE-BLOOD-AND-BLOOD-FORMING-ORGANS-WITH-MCC

    Other O.R. Procedures of the Blood and Blood Forming Organs with MCC: Inpatient Reimbursement Overview

    803-OTHER-O-R-PROCEDURES-OF-THE-BLOOD-AND-BLOOD-FORMING-ORGANS-WITH-CC

    Other O.R. Procedures of the Blood and Blood Forming Organs with CC: Inpatient Reimbursement Overview

    804-OTHER-O-R-PROCEDURES-OF-THE-BLOOD-AND-BLOOD-FORMING-ORGANS-WITHOUT-CC-MCC

    Other O.R. Procedures of the Blood and Blood Forming Organs without CC/MCC: Inpatient Reimbursement Overview

    808-MAJOR-HEMATOLOGICAL-AND-IMMUNOLOGICAL-DIAGNOSES-EXCEPT-SICKLE-CELL-CRISIS-AND-COAGULATION-DISORDERS-WITH-MCC

    Major Hematological and Immunological Diagnoses: Inpatient Reimbursement Overview

    809-MAJOR-HEMATOLOGICAL-AND-IMMUNOLOGICAL-DIAGNOSES-EXCEPT-SICKLE-CELL-CRISIS-AND-COAGULATION-DISORDERS-WITH-CC

    Major Hematological and Immunological Diagnoses: Inpatient Reimbursement Overview

    810-MAJOR-HEMATOLOGICAL-AND-IMMUNOLOGICAL-DIAGNOSES-EXCEPT-SICKLE-CELL-CRISIS-AND-COAGULATION-DISORDERS-WITHOUT-CC-MCC

    Major Hematological and Immunological Diagnoses: Inpatient Reimbursement Overview

    811-RED-BLOOD-CELL-DISORDERS-WITH-MCC

    Red Blood Cell Disorders with MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 14

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.